# ICARE Epilepsy Research Portfolio Analysis

ICARE meeting April 13, 2015



#### Goals for a comprehensive analysis

- to better inform the ICARE group and interested public about the funding landscape for epilepsy research
- to assess progress being made against the epilepsy research priorities as defined by the 2014 NINDS Benchmarks and the recommendations from the 2012 IOM report "Epilepsy Across the Spectrum".
- to help guide future funding priorities by highlighting current gaps and opportunities in epilepsy research

#### **Analysis Design**


- A working group was established to set the goals and design of the analysis
- Data was collected in four different areas:
  - I. Award Information project, investigator(s), award type and amount
  - 2. Award Research Categories research classification, type, and epilepsy type
  - 3. NINDS 2014 Benchmark Areas
  - 4. IOM 2012 Recommendations
- All ICARE member organizations categorized their funded epilepsy research according to the four areas.
- Data contributed by: NIH, CDC, VA, PCORI, CURE, TS Alliance, AES, EF, and ELC (Dravet Syndrome Foundation, Phelan-McDermid Syndrome Foundation and PCDH 19 Alliance).

#### The ICARE Epilepsy portfolio analysis working group

Jan Buelow, EF
David Eckstein, NCATS, NIH
Margaret Jacobs, AES
Mary Anne Meskis, Dravet Foundation – ELC
Julie Milder, CURE
Rob Moss, Seizure Tracker – ELC
Steve Roberds, TSA

Tom Cheever, NINDS Brandy Fureman, NINDS Miriam Leenders, NINDS


## Federal Funding Dramatically Outpaces Non-profit Funding for Epilepsy Research




## Federal vs Nonprofit Funding for Epilepsy Research in 2013 (total funding \$148.9M)

Funding Agency/Organization	Number of projects	Total Funding
NIH	393	\$136,385,334
CURE	41	\$4,285,114
VA	15	\$2,325,000
CDC	10	\$2,212,135
PCORI	2	\$1,684,562
EF	15	\$730,000
AES	17	\$547,500
Dravet Syndrome Foundation	6	\$435,500
Tuberous Sclerosis Alliance	6	\$174,322
<b>Phelan-McDermid Syndrome Foundation</b>	1	\$50,000
PCDH19 Alliance	I	\$30,000
Grand Total	507	\$148,859,467

#### NINDS Supports Large Majority of NIH Funding



#### CURE Supports Large Majority of Epilepsy Leadership Council (ELC) Funding



#### Most Investigators are Supported by a Single Project







81% of investigators have 1 project; 15% have 2 projects, 2% have 3, 1% have 4 and 1% have 5.

5% of investigators received >\$IM in funding in FY2013


#### Most Funded Epilepsy Research is Basic




#### Most Funded Epilepsy Research is on Mechanism of Disease or Treatment




## Largest Fraction of Funding goes to Research on Mechanism of Disease; Smallest to Prevention



#### Funding for Structured Training in Epilepsy Research is a Small Percentage of Overall Funding




## Funding for Structured Training is Provided by a Subset of Organizations



#### Majority of Training and Career Development Awards Support Basic Research

#### Investment of training awards by Research Classification and Type




### Degrees of training awardees

	# of
Degree	trainees
PHD	48
MD, PHD	18
MD	14
MS	3
BS	7
other	2

#### NIH Epilepsy Career Development Award Funding Decrease Between FY2008 – FY2013

#### **NIH RCDC Epilepsy category K-award funding**



## NIH Epilepsy Career Development Award Funding Decreased More Compared to Other Diseases

#### NIH RCDC disease categories K-award funding

	20	08	2013						
NIH RCDC Disease Category	K awards (M \$)	% of total (\$)	K awards (M \$)	% of total (\$)					
Epilepsy	<b>\$9.1</b>	6.3%	<b>\$5.7</b>	4.4%					
Stroke	\$11.6	3.9%	\$9.9	3.5%					
Parkinson's	\$6.0	4.0%	\$5.6	4.1%					
Brain Cancer	<b>\$5.</b> I	2.6%	\$6.I	2.2%					
Multiple Sclerosis	\$5.0	3.0%	\$3.0	2.7%					
ALS	\$0.9	2.1%	\$1.1	2.8%					
Autism	<b>\$4.</b> I	3.5%	\$5.3	2.9%					


## NIH R01 funding obtained by NS Epilepsy K Awardees

Active K award in FY 2008,2009 or 2010, and		
the award has ended before 2015.	# of awardees	% of awardees
NS Epilepsy K-awardees	53	
applied for R01 funding	38	72%
awarded R01 funding	29	55%
project focused on Epilepsy	22	76% of R01s

#### Disparities in Funding for Different Epilepsy Types

Age of onset:	Neonatal/ Infantile	Childhood	Adolescent/ Adult	Variable Age	Type not specified
NIH	<b>12%</b>	• 5%	20%	37%	25%
CURE	40%	• 1%	• 6%	36%	<b>17</b> %
VA			19%	32%	48%
CDC		<b>18</b> %	<b>1</b> 4%		68%
PCORI		59%		41%	
EF		• 6%	• 3%	90%	
AES	25%	<b>1</b> 6%	• 11%	36%	<b>12%</b>
Dravet F	100%				
TSA	• 4%	• 1%		95%	
Phelan-M				100%	
PCDH19		100%			
Total	<b>•</b> 13%	• 6%	19%	37%	25%


## Research on the Causes and Consequences of Epilepsy Receives Less Funding



#### Disparities in Funding across Benchmark Areas

	Area I Area II (causes) (epileptogenesis)						Area III							Area IV							
		(caı	uses	<b>5)</b>	(ep	oilep	otog	ene	esis)	(treatment)					(consequences)						
	A	В	C	D	Α	В	C	D	E	Α	В	C	D	Ε	F	G	Α	В	C	D	E
NIH	0.4%	5.3%	0.9%	3.4%	10.5%	17.5%	1.8%	1.0%	2.0%	4.6%	0.6%	2.8%	23.5%	2.9%		0.1%	6.6%	3.0%		1.2%	2.0%
CURE	3.8%	4.1%		6.7%		12.1%	4.9%	4.8%	16.9%	2.8%		4.8%	4.3%	25.5%			1.2%			8.2%	
VA	7.4%	2.8%	2.1%	1.5%	5.3%	11.4%	3.4%	14.09	% 6.7% •	6.0%		14.6%	6.5%	7.8%			3.5%	3.5%	3.5%		
EF	2.3%	4.0%	13.5%		2.3%		3.4%		8.2%	5.6%			57.4%						3.4%		
AES	21.3%	8.5%			15.3%	20.4%	8.1%	1.7%	1.7%				6.8%		4.3%		8.5%	3.4%			
Dravet F	15.4%		6.2%	1.9%	21.6%		3.8%		14.49	2.5%	15.4%		10.6%	3.8%			2.5%	1.9%			
TSA			30.2%		17.1%		10.7%							38.9%	1.6%	1.6%					
Phelan-M			16.7%	16.7%	16.7%		16.7%			16.7%	16.7%										
PCDH19				100.0%	•																
Total	10.2%	5.2%	1.0%	3.4%	10.1%	17.1%	2.0%	1.3%	2.6%	4.5%	0.6%	2.9%	22.7%	3.7%	0.0%	0.1%	6.3%	2.9%	0.1%	1.4%	1.9%

## Little Funding Dedicated to 2012 IOM Recommendations



- I. Validate and Implement Standard
  Definitions and Criteria for Epilepsy Case
  Ascertainment, Health Care and Community
  Services Use and Costs, and Quality-of-Life
  Measurement
- 2. Continue and Expand Collaborative Surveillance and Data Collection Efforts
- 3. Develop and Evaluate Prevention Efforts for Epilepsy and Its Consequences
- 4. Improve the Early Identification of Epilepsy and Its Comorbid Health Conditions
- 5. Develop and Implement a National Quality Measurement and Improvement Strategy for Epilepsy Care
- 7. Improve Health Professional Education About the Epilepsies
- 9. Improve and Expand Educational
  Opportunities for People with Epilepsy and
  Their Families

#### Conclusions from 2013 Funding Data

- 1) Epilepsy research funding spans a range of organizations with different missions and funding capacity
- 2) Federal funding significantly outpaces nonprofit research funding
- 3) Funding from federal sources is highly concentrated at NIH
- 4) Limited Support for structured training in epilepsy research; is this sufficient?
- 5) Epilepsy research funding is unevenly distributed among the Epilepsy Benchmark priorities
- 6) Epilepsy research funding for IOM Research Recommendations is very limited.